ACBM · XBRL financial data
Acro Biomedical financial statements, every quarter
The same tables from 12 filings, lined up. Matched by XBRL tag: renamed lines keep their history.
How these numbers work
- Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
- Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
- * marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
- 0 means a filing states zero; a dash (—) means no filing states that number.
- “year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
- Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
- Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
- Shares outstanding come from each filing's cover page, as of the date printed there.
- Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.
Income statement
CSVFiscal quarters (ACBM's year ends in late December)
| In thousands of dollars | Sep 30, 2023 | Dec 31, 2023 | Mar 31, 2024 | Jun 30, 2024 | Sep 30, 2024 | Dec 31, 2024 | Mar 31, 2025 | Jun 30, 2025 | Sep 30, 2025 | Dec 31, 2025 | Mar 31, 2026 | Jun 30, 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0* | 0 | 0 | 0 | 0* | 0 | 0 | 0 | 0* | 0 | 0 |
| Cost of revenue | 0 | 0* | — | — | — | — | — | — | — | — | — | — |
| Gross profit | 0 | 0* | — | — | — | — | — | — | — | — | — | — |
| Research and development | 397 | 0* | 0 | 0 | 0 | 0* | — | — | — | — | — | — |
| Selling, general and administrative | 700 | 17* | 10 | 9 | 9 | 9* | 9 | 14 | 115 | 16* | 60 | 18 |
| Total operating expenses | 1,589 | 17* | 10 | 9 | 9 | 9* | 9 | 14 | 115 | 16* | 60 | 18 |
| Operating income (loss) | (1,589) | (17)* | (10) | (9) | (9) | (9)* | (9) | (14) | (115) | (16)* | (60) | (18) |
| Interest expense | — | year only | — | — | — | — | — | — | — | — | — | — |
| Other income (expense) | — | — | — | — | — | year only | (1) | (2) | — | year only | 16 | (4) |
| Income tax expense (benefit) | 0 | 0* | 0 | 0 | 0 | 0* | 0 | 0 | 0 | 0* | — | — |
| Net income (loss) | (1,589) | (18)* | (11) | (10) | (10) | (11)* | (10) | (16) | (118) | 43* | (44) | (21) |
| Earnings per share, diluted USD per share | (0.03) | 0.00* | 0.00 | 0.00 | 0.00 | 0.00* | 0.00 | 0.00 | 0.00 | 0.00* | 0.00 | 0.00 |
| Weighted average shares, diluted thousands of shares | 60,042 | 60,042* | 60,042 | 60,042 | 60,042 | 60,042* | 60,042 | 60,042 | 60,042 | 60,042* | 60,042 | 60,042 |
Balance sheet
CSVFiscal quarters (ACBM's year ends in late December)
| In thousands of dollars | Sep 30, 2023 | Dec 31, 2023 | Mar 31, 2024 | Jun 30, 2024 | Sep 30, 2024 | Dec 31, 2024 | Mar 31, 2025 | Jun 30, 2025 | Sep 30, 2025 | Dec 31, 2025 | Mar 31, 2026 | Jun 30, 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash and cash equivalents | 3 | 0 | 0 | 1 | 1 | 0 | 0 | 0 | 4 | 4 | 4 | 4 |
| Accounts receivable | 0 | 0 | — | — | — | — | — | — | — | — | — | — |
| Total current assets | 13 | 2 | 0 | 1 | 1 | 5 | 5 | 40 | 4 | 14 | 4 | 4 |
| Right-of-use asset | 7 | 52 | 46 | 40 | 33 | 27 | 20 | 14 | 0 | 0 | — | — |
| Total assets | 19 | 58 | 51 | 45 | 39 | 32 | 25 | 53 | 4 | 14 | 4 | 4 |
| Accounts payable | — | — | — | — | — | — | — | — | — | 56 | — | 63 |
| Total current liabilities | 259 | 289 | 298 | 308 | 317 | 327 | 329 | 371 | 437 | 401 | 431 | 448 |
| Lease liability, non-current | — | 27 | 20 | 14 | 7 | 0 | 0 | 0 | — | — | — | — |
| Total liabilities | 259 | 315 | 318 | 322 | 324 | 327 | — | — | — | — | — | — |
| Accumulated deficit | (32,597) | (32,615) | (32,627) | (32,637) | (32,647) | (32,658) | (32,668) | (32,684) | (32,801) | (32,759) | (32,803) | (32,824) |
| Total stockholders' equity | (240) | (257) | (267) | (276) | (286) | (295) | (304) | (318) | (433) | (387) | (427) | (445) |
| Total liabilities and equity | 19 | 58 | 51 | 45 | 39 | 32 | 25 | 53 | 4 | 14 | 4 | 4 |
| Common shares outstanding (cover page) thousands of shares | 60,042 | 60,042 | 60,042 | 60,042 | 60,042 | 60,042 | 60,042 | 60,042 | 60,042 | 60,042 | 60,042 | 60,042 |
Cash flows
CSVFiscal quarters (ACBM's year ends in late December)
| In thousands of dollars | Sep 30, 2023 | Dec 31, 2023 | Mar 31, 2024 | Jun 30, 2024 | Sep 30, 2024 | Dec 31, 2024 | Mar 31, 2025 | Jun 30, 2025 | Sep 30, 2025 | Dec 31, 2025 | Mar 31, 2026 | Jun 30, 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net income (loss) | (1,589) | (18)* | (11) | (10) | (10) | (11)* | (10) | (16) | (118) | 43* | (44) | (21) |
| Stock-based compensation | 1,009 | 0* | — | — | — | year only | — | — | — | — | — | — |
| Net cash from operating activities | 0* | (13)* | (14) | (6)* | (6)* | (11)* | (23) | (94)* | (54)* | (25)* | (50) | (11)* |
| Net cash from financing activities | 0* | 10* | 13 | 7* | 6* | 10* | 22 | 94* | 59* | 25* | 50 | 10* |
Compare with peers
SIC 7900 and related industry codes, similar size; rows marked “added: same SIC” fill a short list. Each row is the latest quarter reported.
How peers are chosen
- SIC 7900 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
- Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
- Fewer than three companies fall in that range, so the list adds same-SIC (7900) companies nearest in public float, each marked “added: same SIC”.
- Runway shows only for companies burning cash with under $10B of public float.
- * marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.
| Company | Cash ($K) | Revenue, quarter ($K) | Operating cash flow, quarter ($K) | Shares outstanding | Runway | Quarter |
|---|---|---|---|---|---|---|
| Acro Biomedical | 3.6 | 0 | (11)* | 60.0M | 0.3 quarters | 10-QJun 30, 2026 |
| Scores Holding | 87 | 53 | 6.1* | 165.2M | — | 10-QSep 30, 2025 |
| SportsQuestadded: same SIC | 15 | 0 | (31)* | 4.0B | 0.5 quarters | 10-QJun 30, 2026 |
| Loan Artificial Intelligenceadded: same SIC | 0 | 0 | (3)* | 454,365 | — | 10-QJun 30, 2026 |
| Lingerie Fighting Championshipsadded: same SIC | 19 | 30 | (59)* | 1.9M | 0.3 quarters | 10-QJun 30, 2026 |
| Mobile Global Esportsadded: same SIC | 20 | 16 | (353)* | 183.8M | 0.1 quarters | 10-QJun 30, 2026 |
| Flash Sports & Media Holdingsadded: same SIC | 2,389 | 44 | (2,706)* | 56.7M | 0.9 quarters | 10-QJun 30, 2026 |
| High Roller Technologiesadded: same SIC | 18,009 | 2,809 | (2,882)* | 11.0M | 6.2 quarters | 10-Q/AJun 30, 2026 |
| American Picture Houseadded: same SIC | 0 | 0 | (38)* | 114.7M | 0.0 quarters | 10-QJun 30, 2026 |
Not investment advice. Not affiliated with the U.S. SEC.